DELCATH SYSTEMS, INC.
No SEC Form 4 filings for $DCTH in the last 30 days.
See all $DCTH insider activity →Delcath Systems (DCTH) reported Q2 revenue of $29.1M, up from $24.2M YoY, driven by its HEPZATO KIT and CHEMOSAT devices. The company raised its 2026 revenue guidance to $104M-$108M. However, expenses rose, with R&D and SG&A increasing, leading to flat net income. Delcath has $95.9M in cash and no debt, and is expanding into new indications.
DELCATH SYSTEMS, INC. (DCTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Delcath Systems Reports Second Quarter 2026 Results and Business Highlights Increases 2026 Revenue Guidance to a Range of $104M to $108M Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, NY – August 6, 2026, Delcath Systems, Inc. (Nasdaq: DCTH), an interven
Delcath Systems (Nasdaq: DCTH) said the first patient was dosed in its Phase 2 DELUMA trial of HEPZATO plus standard of care versus standard of care alone for liver-dominant HER2-negative metastatic breast cancer. The randomized study will enroll about 90 patients at 20+ sites in the US and Europe, with hepatic progression-free survival as the primary endpoint.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning DCTH (DELCATH SYSTEMS, INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent DCTH coverage spans financial news, earnings and technology.
Guidance raise may boost short-term upside; higher expenses could pressure margins.
Guidance and quarterly momentum around HEPZATO KIT usage are the key near-term drivers for DCTH’s valuation and positioning.
First-patient dosing de-risks trial execution and can improve near-term sentiment, but it is not efficacy data.
The presentation of positive data (60% hepatic partial response) at ESMO could bolster investor confidence in DCTH, potentially leading to a short-term price increase. However, safety considerations and the heavily pretreated patient population suggest cautious optimism.
Despite reported profit growth over the past five quarters, Delcath Systems faces a valuation downgrade due to unfavorable financial ratios and technical indicators, suggesting limited short-term trading opportunities.
AlphAI scores every news story that mentions DCTH with an AI model for sentiment and relevance, and aggregates insider trades from DELCATH SYSTEMS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Delcath Systems (DCTH) reported Q2 revenue of $29.1M, up from $24.2M YoY, driven by its HEPZATO KIT and CHEMOSAT devices. The company raised its 2026 revenue guidance to $104M-$108M. However, expenses rose, with R&D and SG&A increasing, leading to flat net income. Delcath has $95.9M in cash and no debt, and is expanding into new indications.
3 min readDELCATH SYSTEMS, INC. (DCTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Delcath Systems Reports Second Quarter 2026 Results and Business Highlights Increases 2026 Revenue Guidance to a Range of $104M to $108M Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, NY – August 6, 2026, Delcath Systems, Inc. (Nasdaq: DCTH), an interven
6 min readDelcath Systems (Nasdaq: DCTH) said the first patient was dosed in its Phase 2 DELUMA trial of HEPZATO plus standard of care versus standard of care alone for liver-dominant HER2-negative metastatic breast cancer. The randomized study will enroll about 90 patients at 20+ sites in the US and Europe, with hepatic progression-free survival as the primary endpoint.
3 min readDelcath Systems announced new data from a retrospective analysis on percutaneous hepatic perfusion with melphalan (M-PHP) using the CHEMOSAT Hepatic Delivery System for liver-dominant metastatic breast cancer. The data, presented at the ESMO Breast Cancer Congress 2026, showed hepatic partial response in 60% of evaluable patients and highlighted safety considerations like blood transfusions and transient bone marrow suppression. This real-world evidence supports further evaluation of HEPZATO KIT and CHEMOSAT in this heavily pretreated patient population.
2 min readDelcath Systems, Inc., a microcap biopharmaceutical company, has seen its valuation grade shift from attractive to expensive due to changing financial metrics, despite reporting positive pre-tax and net profit growth over the past five quarters. The company faces a complex financial landscape with negative EV to EBIT and EV to EBITDA ratios, and its stock's technical trend has moved to mildly bearish. This re-evaluation highlights the evolving financial dynamics for Delcath Systems within the competitive biotechnology sector.
3 min readInvestors need to pay close attention to Delcath Systems stock based on the movements in the options market lately.
3 min readDelcath Systems (DCTH) delivered earnings and revenue surprises of 0.00% and +0.41%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
2 min readShares of Delcath Systems Inc ( NASDAQ:DCTH ) rose sharply in pre-market trading after the company announced preliminary third quarter 2025 financial results. The company's Phase 2 CHOPIN study achieved primary endpoint, with PHP plus immunotherapy extending median PFS to 12.8 months versus ...
3 min readDelcath Systems ( NASDAQ:DCTH ) , a medical device and pharmaceutical company known for liver-directed cancer therapies, announced its earnings for the second quarter of fiscal 2025 on August 6, 2025. The company reported a sharp increase in revenue, reaching $24.2 million ( GAAP ) .-exceeding ...
2 min readDoes Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 min read
